PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930149
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930149
Cephalosporin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Growth Factors of cephalosporin Market
The global cephalosporin market is demonstrating steady growth, supported by the increasing burden of bacterial infections and the rising demand for broad-spectrum antibiotics. The market was valued at USD 8.32 billion in 2025 and is projected to grow to USD 8.73 billion in 2026, reaching USD 13.62 billion by 2034, registering a CAGR of 5.72% during the forecast period. North America dominated the market with a 47.05% share in 2025, driven by advanced healthcare infrastructure and high prescription volumes.
Cephalosporins are B-lactam antibiotics that inhibit bacterial cell wall synthesis, leading to bacterial cell death. These antibiotics are widely used to treat infections such as urinary tract infections, respiratory infections, skin and soft tissue infections, pneumonia, and meningitis. The continuous emergence of antimicrobial resistance (AMR) has accelerated the development of newer-generation cephalosporins with enhanced efficacy against resistant strains.
Market Dynamics
Market Drivers
The increasing number of new product launches by key pharmaceutical players is a major driver of market growth. Rising antibiotic resistance has compelled companies to invest heavily in R&D to develop advanced cephalosporins such as ceftaroline and ceftobiprole, which are effective against multidrug-resistant bacteria.
For instance, in April 2024, Basilea Pharmaceutica Ltd received U.S. FDA approval for ZEVTERA (ceftobiprole) for bloodstream infections, acute bacterial skin infections, and community-acquired bacterial pneumonia. Such approvals significantly boost market demand.
Market Restraints
The market growth is restrained by adverse effects associated with cephalosporins, including gastrointestinal complications and allergic reactions. Moreover, reports of neurotoxicity, particularly among elderly patients and those receiving high intravenous doses, have raised safety concerns.
In March 2023, New Zealand's Medicines Adverse Reaction Committee highlighted neurological side effects such as seizures and encephalopathy, prompting cautious prescription practices and limiting widespread adoption.
Market Opportunities
Advancements in drug delivery systems and nanoparticle-based formulations present significant growth opportunities. Research studies are focusing on converting older-generation cephalosporins into nano-antibiotics using gold and silver nanoparticles to improve potency, reduce dosage frequency, and overcome resistance.
In January 2023, an NIH study demonstrated that ineffective cephalosporins could be transformed into potent nano-antibiotics using gold nanoparticles, offering a promising avenue for market expansion.
Market Challenges
Strict regulatory frameworks aimed at controlling AMR pose a major challenge. Governments worldwide are enforcing antibiotic stewardship programs to restrict overuse.
For example, in October 2024, the Indian Council of Medical Research (ICMR) reported high resistance levels among UTI-causing pathogens against third-generation cephalosporins, emphasizing the need for controlled prescribing.
Cephalosporin Market Trends
A key market trend is the rising popularity of combination therapies, where cephalosporins are used alongside B-lactamase inhibitors to improve clinical outcomes against resistant infections. Additionally, the growing preference for injectable formulations due to faster action and targeted delivery is shaping production strategies.
In June 2024, Sands Active Ltd. launched a cephalosporin injectable manufacturing plant in Sri Lanka, highlighting this trend.
Segmentation Analysis
By generation, the third-generation cephalosporins segment is expected to dominate due to its broad-spectrum activity and widespread use in respiratory and skin infections.
By route of administration, the oral segment is projected to grow significantly due to ease of use and rising self-medication, while the parenteral segment shows strong growth driven by hospital demand.
By disease indication, urinary tract infections hold the largest share, supported by the rising prevalence of hospital-acquired UTIs.
By distribution channel, hospital pharmacies dominate due to high prescription volumes.
Regional Outlook
North America led the market with a valuation of USD 3.89 billion in 2025 and USD 4.09 billion in 2026, driven by high rates of hospital-acquired infections.
Europe holds the second-largest share due to increased consumption of second- and third-generation cephalosporins.
Asia Pacific is expected to register the highest CAGR, supported by large-scale API production and rising healthcare investments.
Latin America and the Middle East & Africa are anticipated to witness moderate growth owing to improving regulatory frameworks and manufacturing capacity expansion.
Competitive Landscape
The market is semi-consolidated, with key players including Pfizer Inc., Sandoz Group AG, Merck & Co., Inc., AbbVie Inc., GSK plc., Astellas Pharma Inc., and Shionogi & Co., Ltd. These companies focus on R&D investments, strategic collaborations, and capacity expansion to strengthen their market presence.
Conclusion
The global cephalosporin market is expected to grow steadily through 2034, driven by rising bacterial infections, continuous product innovations, and the urgent need to combat antimicrobial resistance. Although adverse effects and strict regulatory controls pose challenges, advancements in combination therapies, nanoparticle-based drug delivery, and injectable formulations are creating new growth opportunities. With North America maintaining dominance and Asia Pacific emerging as a high-growth region, the cephalosporin market is well-positioned for sustained expansion, reinforcing its critical role in modern infectious disease management.
Segmentation
By Generation
- First Generation
- Second Generation
- Third Generation
- Fourth Generation
- Others
By Route of Administration
- Oral
- Parenteral
By Disease Indications
- Urinary Tract Infections
- Skin & Soft Tissue infection
- Respiratory Infections
- Meningitis
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Region
- North America (By Generation, Route of Administration, Disease Indications, Distribution Channel, and Country/sub-region)
- U.S.
- Canada
- Europe (By Generation, Route of Administration, Disease Indications, Distribution Channel, and Country/sub-region)
- Germany
- U.K.
- France
- Italy
- Spain
- Scandinavia
- Rest of Europe
- Asia Pacific (By Generation, Route of Administration, Disease Indications, Distribution Channel, and Country/sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Generation, Route of Administration, Disease Indications, Distribution Channel, and Country/sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Generation, Route of Administration, Disease Indications, Distribution Channel, and Country/sub-region)
- GCC
- South Africa
- Rest of the Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Pipeline Analysis, By Key Players
- 4.2. Overview of Antimicrobial Treatment Guidelines
- 4.3. Overview of the Antibiotic resistant "Priority Pathogens" Published by WHO
- 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
- 4.5. New Product Launches, By Key Players
5. Global Cephalosporin Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Generation
- 5.1.1. First Generation
- 5.1.2. Second Generation
- 5.1.3. Third Generation
- 5.1.4. Fourth Generation
- 5.1.5. Others
- 5.2. Market Analysis, Insights and Forecast - By Route of Administration
- 5.2.1. Oral
- 5.2.2. Parenteral
- 5.3. Market Analysis, Insights and Forecast - By Disease Indication
- 5.3.1. Urinary Tract Infections
- 5.3.2. Skin & Soft Tissue Infections
- 5.3.3. Respiratory Infections
- 5.3.4. Meningitis
- 5.3.5. Others
- 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.4.1. Hospital Pharmacy
- 5.4.2. Retail Pharmacy
- 5.4.3. Online Pharmacy
- 5.5. Market Analysis, Insights and Forecast - By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
6. North America Cephalosporin Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Generation
- 6.1.1. First Generation
- 6.1.2. Second Generation
- 6.1.3. Third Generation
- 6.1.4. Fourth Generation
- 6.1.5. Others
- 6.2. Market Analysis, Insights and Forecast - By Route of Administration
- 6.2.1. Oral
- 6.2.2. Parenteral
- 6.3. Market Analysis, Insights and Forecast - By Disease Indication
- 6.3.1. Urinary Tract Infections
- 6.3.2. Skin & Soft Tissue Infections
- 6.3.3. Respiratory Infections
- 6.3.4. Meningitis
- 6.3.5. Others
- 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.4.1. Hospital Pharmacy
- 6.4.2. Retail Pharmacy
- 6.4.3. Online Pharmacy
- 6.5. Market Analysis, Insights and Forecast - By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Cephalosporin Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Generation
- 7.1.1. First Generation
- 7.1.2. Second Generation
- 7.1.3. Third Generation
- 7.1.4. Fourth Generation
- 7.1.5. Others
- 7.2. Market Analysis, Insights and Forecast - By Route of Administration
- 7.2.1. Oral
- 7.2.2. Parenteral
- 7.3. Market Analysis, Insights and Forecast - By Disease Indication
- 7.3.1. Urinary Tract Infections
- 7.3.2. Skin & Soft Tissue Infections
- 7.3.3. Respiratory Infections
- 7.3.4. Meningitis
- 7.3.5. Others
- 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.4.1. Hospital Pharmacy
- 7.4.2. Retail Pharmacy
- 7.4.3. Online Pharmacy
- 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 7.5.1. U.K.
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Spain
- 7.5.5. Italy
- 7.5.6. Scandinavia
- 7.5.7. Rest of Europe
8. Asia Pacific Cephalosporin Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Generation
- 8.1.1. First Generation
- 8.1.2. Second Generation
- 8.1.3. Third Generation
- 8.1.4. Fourth Generation
- 8.1.5. Others
- 8.2. Market Analysis, Insights and Forecast - By Route of Administration
- 8.2.1. Oral
- 8.2.2. Parenteral
- 8.3. Market Analysis, Insights and Forecast - By Disease Indication
- 8.3.1. Urinary Tract Infections
- 8.3.2. Skin & Soft Tissue Infections
- 8.3.3. Respiratory Infections
- 8.3.4. Meningitis
- 8.3.5. Others
- 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.4.1. Hospital Pharmacy
- 8.4.2. Retail Pharmacy
- 8.4.3. Online Pharmacy
- 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 8.5.1. Japan
- 8.5.2. China
- 8.5.3. India
- 8.5.4. Australia
- 8.5.5. Southeast Asia
- 8.5.6. Rest of Asia Pacific
9. Latin America Cephalosporin Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Generation
- 9.1.1. First Generation
- 9.1.2. Second Generation
- 9.1.3. Third Generation
- 9.1.4. Fourth Generation
- 9.1.5. Others
- 9.2. Market Analysis, Insights and Forecast - By Route of Administration
- 9.2.1. Oral
- 9.2.2. Parenteral
- 9.3. Market Analysis, Insights and Forecast - By Disease Indication
- 9.3.1. Urinary Tract Infections
- 9.3.2. Skin & Soft Tissue Infections
- 9.3.3. Respiratory Infections
- 9.3.4. Meningitis
- 9.3.5. Others
- 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.4.1. Hospital Pharmacy
- 9.4.2. Retail Pharmacy
- 9.4.3. Online Pharmacy
- 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
10. Middle East & Africa Cephalosporin Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Generation
- 10.1.1. First Generation
- 10.1.2. Second Generation
- 10.1.3. Third Generation
- 10.1.4. Fourth Generation
- 10.1.5. Others
- 10.2. Market Analysis, Insights and Forecast - By Route of Administration
- 10.2.1. Oral
- 10.2.2. Parenteral
- 10.3. Market Analysis, Insights and Forecast - By Disease Indication
- 10.3.1. Urinary Tract Infections
- 10.3.2. Skin & Soft Tissue Infections
- 10.3.3. Respiratory Infections
- 10.3.4. Meningitis
- 10.3.5. Others
- 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.4.1. Hospital Pharmacy
- 10.4.2. Retail Pharmacy
- 10.4.3. Online Pharmacy
- 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 10.5.1. GCC
- 10.5.2. South Africa
- 10.5.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. Pfizer Inc.
- 11.2.1.1. Overview
- 11.2.1.2. Products & services
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Sandoz Group AG
- 11.2.2.1. Overview
- 11.2.2.2. Products & services
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Merck & Co., Inc.,
- 11.2.3.1. Overview
- 11.2.3.2. Products & services
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. AbbVie Inc.
- 11.2.4.1. Overview
- 11.2.4.2. Products & services
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. Bayer AG
- 11.2.5.1. Overview
- 11.2.5.2. Products & services
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. Astellas Pharma Inc.
- 11.2.6.1. Overview
- 11.2.6.2. Products & services
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. Shionogi & Co., Ltd
- 11.2.7.1. Overview
- 11.2.7.2. Products & services
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Abbott
- 11.2.8.1. Overview
- 11.2.8.2. Products & services
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.1. Pfizer Inc.
List of Tables
- Table 1: Global Cephalosporin Market Revenue (USD billion) Forecast, by Generation, 2021-2034
- Table 2: Global Cephalosporin Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 3: Global Cephalosporin Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
- Table 4: Global Cephalosporin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 5: Global Cephalosporin Market Revenue (USD billion) Forecast, by Region, 2021-2034
- Table 6: North America Cephalosporin Market Revenue (USD billion) Forecast, by Generation, 2021-2034
- Table 7: North America Cephalosporin Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 8: North America Cephalosporin Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
- Table 9: North America Cephalosporin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 10: North America Cephalosporin Market Revenue (USD billion) Forecast, by Country, 2021-2034
- Table 11: Europe Cephalosporin Market Revenue (USD billion) Forecast, by Generation, 2021-2034
- Table 12: Europe Cephalosporin Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 13: Europe Cephalosporin Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
- Table 14: Europe Cephalosporin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 15: Europe Cephalosporin Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2021-2034
- Table 16: Asia Pacific Cephalosporin Market Revenue (USD billion) Forecast, by Generation, 2021-2034
- Table 17: Asia Pacific Cephalosporin Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 18: Asia Pacific Cephalosporin Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
- Table 19: Asia Pacific Cephalosporin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 20: Asia Pacific Cephalosporin Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2021-2034
- Table 21: Latin America Cephalosporin Market Revenue (USD billion) Forecast, by Generation, 2021-2034
- Table 22: Latin America Cephalosporin Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 23: Latin America Cephalosporin Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
- Table 24: Latin America Cephalosporin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 25: Latin America Cephalosporin Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2021-2034
- Table 26: Middle East & Africa Cephalosporin Market Revenue (USD billion) Forecast, by Generation, 2021-2034
- Table 27: Middle East & Africa Cephalosporin Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 28: Middle East & Africa Cephalosporin Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
- Table 29: Middle East & Africa Cephalosporin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 30: Middle East & Africa Cephalosporin Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2021-2034
List of Figures
- Figure 1: Global Cephalosporin Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
- Figure 2: Global Cephalosporin Market Value Share (%), by Generation, 2025 & 2034
- Figure 3: Global Cephalosporin Market Value Share (%), by Route of Administration, 2025 & 2034
- Figure 4: Global Cephalosporin Market Value Share (%), by Disease Indication, 2025 & 2034
- Figure 5: Global Cephalosporin Market Value Share (%), by Distribution Channel, 2025 & 2034
- Figure 6: Global Cephalosporin Market Value Share (%), by Region, 2025 & 2034
- Figure 7: North America Cephalosporin Market Value (USD billion), by Generation, 2025 & 2034
- Figure 8: North America Cephalosporin Market Value Share (%), by Generation, 2025
- Figure 9: North America Cephalosporin Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 10: North America Cephalosporin Market Value Share (%), by Route of Administration, 2025
- Figure 11: North America Cephalosporin Market Value (USD billion), by Disease Indication, 2025 & 2034
- Figure 12: North America Cephalosporin Market Value Share (%), by Disease Indication, 2025
- Figure 13: North America Cephalosporin Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 14: North America Cephalosporin Market Value Share (%), by Distribution Channel, 2025
- Figure 15: North America Cephalosporin Market Value (USD billion), by Country, 2025 & 2034
- Figure 16: North America Cephalosporin Market Value Share (%), by Country, 2025
- Figure 17: Europe Cephalosporin Market Value (USD billion), by Generation, 2025 & 2034
- Figure 18: Europe Cephalosporin Market Value Share (%), by Generation, 2025
- Figure 19: Europe Cephalosporin Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 20: Europe Cephalosporin Market Value Share (%), by Route of Administration, 2025
- Figure 21: Europe Cephalosporin Market Value (USD billion), by Disease Indication, 2025 & 2034
- Figure 22: Europe Cephalosporin Market Value Share (%), by Disease Indication, 2025
- Figure 23: Europe Cephalosporin Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 24: Europe Cephalosporin Market Value Share (%), by Distribution Channel, 2025
- Figure 25: Europe Cephalosporin Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
- Figure 26: Europe Cephalosporin Market Value Share (%), by Country/Sub-Region, 2025
- Figure 27: Asia Pacific Cephalosporin Market Value (USD billion), by Generation, 2025 & 2034
- Figure 28: Asia Pacific Cephalosporin Market Value Share (%), by Generation, 2025
- Figure 29: Asia Pacific Cephalosporin Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 30: Asia Pacific Cephalosporin Market Value Share (%), by Route of Administration, 2025
- Figure 31: Asia Pacific Cephalosporin Market Value (USD billion), by Disease Indication, 2025 & 2034
- Figure 32: Asia Pacific Cephalosporin Market Value Share (%), by Disease Indication, 2025
- Figure 33: Asia Pacific Cephalosporin Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 34: Asia Pacific Cephalosporin Market Value Share (%), by Distribution Channel, 2025
- Figure 35: Asia Pacific Cephalosporin Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
- Figure 36: Asia Pacific Cephalosporin Market Value Share (%), by Country/Sub-Region, 2025
- Figure 37: Latin America Cephalosporin Market Value (USD billion), by Generation, 2025 & 2034
- Figure 38: Latin America Cephalosporin Market Value Share (%), by Generation, 2025
- Figure 39: Latin America Cephalosporin Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 40: Latin America Cephalosporin Market Value Share (%), by Route of Administration, 2025
- Figure 41: Latin America Cephalosporin Market Value (USD billion), by Disease Indication, 2025 & 2034
- Figure 42: Latin America Cephalosporin Market Value Share (%), by Disease Indication, 2025
- Figure 43: Latin America Cephalosporin Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 44: Latin America Cephalosporin Market Value Share (%), by Distribution Channel, 2025
- Figure 45: Latin America Cephalosporin Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
- Figure 46: Latin America Cephalosporin Market Value Share (%), by Country/Sub-Region, 2025
- Figure 47: Middle East & Africa Cephalosporin Market Value (USD billion), by Generation, 2025 & 2034
- Figure 48: Middle East & Africa Cephalosporin Market Value Share (%), by Generation, 2025
- Figure 49: Middle East & Africa Cephalosporin Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 50: Middle East & Africa Cephalosporin Market Value Share (%), by Route of Administration, 2025
- Figure 51: Middle East & Africa Cephalosporin Market Value (USD billion), by Disease Indication, 2025 & 2034
- Figure 52: Middle East & Africa Cephalosporin Market Value Share (%), by Disease Indication, 2025
- Figure 53: Middle East & Africa Cephalosporin Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 54: Middle East & Africa Cephalosporin Market Value Share (%), by Distribution Channel, 2025
- Figure 55: Middle East & Africa Cephalosporin Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
- Figure 56: Middle East & Africa Cephalosporin Market Value Share (%), by Country/Sub-Region, 2025
- Figure 57: Global Cephalosporin Market Share (%), by Company, 2025
